← Back to Search

Alpha-2 Adrenergic Agonist

Latanoprost for Ocular Hypertension

N/A
Waitlist Available
Led By Joseph I. Markoff, Ph.D,M.D
Research Sponsored by Philadelphia Eye Associates
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 5 years
Awards & highlights
No Placebo-Only Group
All Individual Drugs Already Approved
Approved for 10 Other Conditions

Summary

The Purpose of This Study is to Determine if Taking an Over the Counter Non-Steroidal Anti-Inflammatory(Ibuprofen)has an Effect on Eye Pressure in Patients using Brimonidine(Alphagan)and Latanoprost(Xalatan) eye drops.

Eligible Conditions
  • Ocular Hypertension
  • Glaucoma

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 5 years
This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 5 years for reporting.

Treatment Details

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.
All Individual Drugs Already Approved
Therapies where all constituent drugs have already been approved are likely to have better-understood side effect profiles.
Approved for 10 Other Conditions
This treatment demonstrated efficacy for 10 other conditions.

Trial Design

3Treatment groups
Active Control
Group I: LatanoprostActive Control2 Interventions
to determine whether commonly used OTC non-steroidal anti-inflammatory agents taken orally has any effect on the ability of either latanoprost or brimonidine to lower high eye pressure
Group II: BrimonidineActive Control2 Interventions
to determine whether commonly used OTC non-steroidal anti-inflammatory agents taken orally has any effect on the ability of either latanoprost or brimonidine to lower high eye pressure
Group III: ibuprofenActive Control2 Interventions
to determine whether commonly used OTC non-steroidal anti-inflammatory agents taken orally has any effect on the ability of either latanoprost or brimonidine to lower high eye pressure

Find a Location

Who is running the clinical trial?

Philadelphia Eye AssociatesLead Sponsor
1 Previous Clinical Trials
PfizerIndustry Sponsor
4,642 Previous Clinical Trials
17,743,018 Total Patients Enrolled
10 Trials studying Ocular Hypertension
2,699 Patients Enrolled for Ocular Hypertension
Joseph I. Markoff, Ph.D,M.DPrincipal InvestigatorPhiladelphia Eye Associates
~3 spots leftby Oct 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top